Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1,021 INR | +1.57% | +11.18% | +12.08% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The company returns high margins, thereby supporting business profitability.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- Analysts covering this company mostly recommend stock overweighting or purchase.
Weaknesses
- The group shows a rather high level of debt in proportion to its EBITDA.
- With an expected P/E ratio at 33.43 and 33.94 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+12.08% | 1.64B | D+ | ||
+48.53% | 780B | C+ | ||
+40.93% | 627B | B | ||
-6.37% | 353B | C+ | ||
+20.93% | 334B | B- | ||
+8.21% | 296B | C+ | ||
+17.38% | 244B | B+ | ||
-1.47% | 217B | A+ | ||
+10.88% | 214B | B- | ||
+4.40% | 161B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ERIS Stock
- Ratings Eris Lifesciences Limited